

DAFTAR PUSTAKA

- Abdallah, C., Udomtecha, D., 2007. Pseudocholinesterase activity: determination and interpretation in pediatric anesthesia. *M.E.J. Anesth*, 19 (2): 423-428.
- Akbar, N., (2014). Kelainan enzim pada penyakit hati. In S. S. Ari W Sudoyo, Bambang Setiyohadi, Idrus Alwi (Ed.), *Buku Ajar ilmu Penyakit Dalam jilid I edisi VI*, pp. 1941-44. Interna Publishing, Jakarta.
- Alianto, R. (2015). Gambaran histopatologi karsinoma hepatoseluler. *Cermin Dunia Kedokteran*. 42(6), 440-444.
- Aquilar, P.B., Vidal, J.C., Palomec, G., Dolores, G.F., *et al.*, 2015. Acetylcholinesterase is associated with a decrease in cell proliferation of hepatocellular carcinoma cells, *Biochimia et Biophysica Acta*. 1852:1380-1387.
- Barash, P.G., Cullen, B.F., Stoelting, R.K., 2006. Handbook of Clinical Anesthesia (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 546-9.
- Brown, S.S., Kalow, W., Pliz, W., Whittaker, Woronick, C.L., 1981. The plasma cholinesterases: a new perspective. *Advances in Clinical Chemistry*. 22:2-5.
- Cahyono, J.S.B., 2014. *Tatalaksana Klinis di Bidang Gastro dan Hepatologi*. Sagung Seto, Jakarta.
- Chowdhary V., Mathur R., Choudhary R., Kamla C., Sonika C., 2014. A study on diagnostic importance of serum cholineesterase activity in hepatic diseases and non-hepatic diseases. *Scholars Journal of Applied Medical Sciences*. 2(6D):3123-3126.
- Dahlan, M.S., 2014. *Statistik untuk kedokteran dan kesehatan*. Salemba Medika, Jakarta.
- Dahlan, M.S., 2016. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan*. Salemba Medika, Jakarta.
- Dhanasekaran R., Limaye A., Cabrera R., 2012. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. *Hepatic Medicine Evidence and research*. 4:19-37.
- Diah, A., Neneng, R., Chatarina, T., 2016. Profil pasien karsinoma hepatoselular di RSUP DR Sardjito Yogyakarta. etd.repository.ugm.ac.id/ind.
- Donadon M., Cimino M., Procopio F., Morengi E., Montorsi M., Torzilli G. 2013. Potential role of cholinesterases to predict short term outcome after hepatic resection for hepatocellular carcinoma. *Update Surg*. 65:11-18 (DOI 110.1007/s13304-012-0174-z).
- El Seraq, H.B., 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*. 142(6):1264-1273. doi:10.1053/j.gastro.2011/12.061.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., *et al.*, 2015. Cancer incidence and mortality worldwide, sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 136(5): E359-86.
- Friedman, SL. 2004. Mechanisms of hepatic fibrosis and therapeutic implications. *Nat Clin Practice Gastroenterol Hepatol*. 1:98-105.

- Gokani R., Jadav P., Shaikh N., Shah R., Chhatriwala M., Patel B., 2014. Serum cholinesterase as diagnostic marker of liver disease. *International Journal of Biomedical and Advance Research*. 05(09):439-442.
- Gomez-Rodriguez, R., Guitierrez, M.R., Varasa, T.A., Frutos, C.G., Dopazo, J.J.C., Perez, G.C., *et al.* 2012. The value of Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. *Revista Espanola De Enfermedades Digestivas*.104:298–304.
- Gorasia, J.H., Kamariya, C., Vachani, U., 2013. Requirement of newer parameters to replace conventional liver function test for differentiation of liver disease from non-liver disease. *International Journal of Scientific and Research*. 3(8):1-3.
- Gupta, D., Lis, C.G., 2010. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. *Nutrition Journal*. 9:69.
- Hanley, J.A., McNeil, B.J., 1982. The Meaning and use of the area under a receiver operating characteristic (ROC) Curve. *Radiology*. 143:29-36.
- Husodo, U.B., 2014. Kanker hati. In S. S. Ari W Sudoyo, Bambang Setiyohadi, Idrus Alwi (Ed.), *Buku Ajar ilmu Penyakit Dalam jilid I edisi IV* (VI, pp. 3030–36). Interna Publishing, Jakarta.
- Kamachi, S., Mizuta, T., Otsuka, T., Nakashita, S., Ide Y., 2015. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. *Hepatology Research*.
- Khan, M.G., 1962. The evaluation of serum pseudocholinesterase as a liver function test. *Ulster Med J*. 1; 31:144-52
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., Tajiri, H. 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World J Hepato*. 7(3):406-424.
- Kurnadihardja, W., 2005. Saluran Empedu dan Hati. Dalam: Ilmu Ajar Bedah. *EGC*. Jakarta. Hal:589-591.
- Ladenheim M.R., Kim N.G., Nguyen P., Le A., Stefanick M.C., Garcia G., 2016. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. *BMJ Open Gastroenterology*. 8 pages (doi:10.1136/bmjgast-2016-000107).
- Lesmana, L.A., Waspo, A.S., Gani, R.A., Hasan, I., Siregar, L., Sulaiman, A.S., *et al.* 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Perhimpunan Peneliti Hati Indonesia. Perhimpunan Dokter Spesialis Patologi Indonesia. Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia. Perkumpulan Subspesialis Radiologi Abdomen Indonesia. Perhimpunan Dokter Spesialis Bedah Digestif Indonesia
- Li, Q., Xing, H., Liu, D., Li, H., 2015. Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. *World Journal of Surgical Oncology*. 13:294.
- Liu, X., Xu, J., 2015. Body mass index and waistline are predictors of survival for hepatocellular carcinoma after hepatectomy. *Medical Science Monitor*. 21:2203-2209.

- Loho, I.M., Hasan, I., Lesmana, C.R., Dewiasty, E., Gani, R.A., 2016. Hepatocellular carcinoma in a tertiary referral hospital in Indonesia: lack of improvement of one-year survival rates between 1998-1999 and 2013-2014. *Asian Pac J Cancer Prev*. 17(4):2165-70.
- McGlynn, K.A., London, W.T., 2011. The global epidemiology of hepatocellular carcinoma, present and future. *Clin Liver Dis*. 15(2):223–x. doi: 10.1016/j.cld.2011.03.006.
- Meng F., Yin X., Ma X., Guo X.D., Jin B., Li H., 2013. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. *Biomedical Reports*. 1:265-68.
- Ogunkeye, O.O., Roluga, A.I., 2006. Serum cholinesterase activity helps to distinguish between liver disease and non liver disease aberration in liver function tests. *Pathophysiology*, 13:91-93.
- Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.J., Lin, S.M., Yoshida, H., *et al.*, 2010. Asian Pacific Association for the Study of the Liver consensus recommendation of hepatocellular carcinoma. *Hepatology International*
- Pons, F., Varela, M., Llovet, J.M., 2005. Staging system in hepatocellular carcinoma. *HPB*. 7:35-41.
- Rao, S.V., Kiran, V.S.R., Indira, S., 2011. A comparative study of pseudocholinesterase and liver function test in cirrhosis of liver, infective hepatitis and obstructive jaundice: a case control study. *Journal of Clinical and Diagnostic Research*, 5(4):729-32.
- Safari, S., Baratloo, A., Elfil, M., Negida, A., 2016. Evidence based emergency medicine; part 5 receiver operating curve and area under the curve. *Emergency*. 4 (2):111-113.
- Santarpia, L., Grandone, I., Contaldo, F., Pasanisi, F., 2013. Butyrylcholinesterase as a prognostic marker: a review of the literature. *J Cachexia Sarcopenia Muscle*. 4: 31-39.
- Siregar, G.A., 2011. Penatalaksanaan non bedah dari karsinoma hati. *Universa Medicina*. 24 (1):35-42.
- Smith, R.L., Loewenthal, H., Lehmann, H., Ryan, E., 1959. A simple colorimetric method for estimating serum pseudocholinesterase. *Clinica Chimica Acta*. 4:384-390.
- Soliday, F.K., Conley, Y.P., Henker, R., 2010. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. *AANA Journal*, 78(4):313-20.
- Schütte, K., Tippelt, B., Schulz, C., Friedrich-wilhelm, R., Malfertheiner, P., Feneberg, A., & Seidensticker, R. (2015). Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). *Clinical Nutrition*, 34, 1122–1127.
- Takeda H., Hiroki N., Iguchi E., Ohara Y., Azuna S., *et al.*, 2013. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. *Molecular and Clinical Oncology*. 1:241-248 (Doi: 10.3892/mco.2012.48).

- Tandon P., and Garcia-Tsao G., 2009. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. *Liver International*: 502- 510. (DOI:10.1111/j.1478-3231.2008.01957.x).
- Waghray, A., Murali, A.R., Narayanan Menon K.V.N., 2015. Hepatocellular carcinoma: from diagnosis to treatment. *World J Hepatol.* 7(8):1020-1029.
- White, B.V., Wetstone, H., Lamotta, R., 1957. Serum cholinesterase activity in malignant neoplasms. *Gastroenterology*, 33:176-181.
- Williams, H.M., Lamotta, R.V., Wetstone, H.J., 1957. Studies of cholinesterase Activity III: Serum cholinesterase in obstructive jaundice and malignant disease. *Gastroenterology*, 33:58.
- Yang D., Hanna D.L., Usher J., LoCoco J., Chaudhari P., Lenz H.J., Setiawan V.W., El-Khoueiry A., 2014. Impact of sex on the survival of patient with hepatocellular carcinoma: A surveillane, epidemiology, and end result analysis, *Cancer*. Vol 120, issue 23:3707-16.
- Zhao, L., Li J., Lun, A.D., Liang, F.J., Ming, P.X., *et al.*, 2014. Enhanced Therapeutic Efficacy of Combined Use of Sorafenib And Transcatheter Arterial ChEmoembolization for Treatment of Advanced Hepatocellular Carcinoma. *Japanese Journal of Clinical Oncology*. 7 pages (doi:10.1093/jjco/hyu068).
- Zhao, Y., Wang X., Wang T., Hu X., Hui X., Yan M., Gao Q., *et al.*, 2011. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. *Hepatology*. 53:493-503.
- Zhu, R. X., Seto, W., Lai, C., & Yuen, M., 2016. Epidemiology of hepatocellular carcinoma in the asia-pacific region. *Gut and Liver*, 10(3):332–339.